[go: up one dir, main page]

WO2000033079A1 - Nanoparticles with polymer shells - Google Patents

Nanoparticles with polymer shells Download PDF

Info

Publication number
WO2000033079A1
WO2000033079A1 PCT/US1999/028387 US9928387W WO0033079A1 WO 2000033079 A1 WO2000033079 A1 WO 2000033079A1 US 9928387 W US9928387 W US 9928387W WO 0033079 A1 WO0033079 A1 WO 0033079A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
monomers
polymer
analyte
attached
Prior art date
Application number
PCT/US1999/028387
Other languages
English (en)
French (fr)
Inventor
Chad A. Mirkin
Sonbinh T. Nguyen
Original Assignee
Nanosphere, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosphere, Inc. filed Critical Nanosphere, Inc.
Priority to EP99962951A priority Critical patent/EP1135682B1/en
Priority to DE69936534T priority patent/DE69936534T2/de
Priority to JP2000585664A priority patent/JP3650582B2/ja
Priority to US09/830,620 priority patent/US7115688B1/en
Priority to CA002352362A priority patent/CA2352362C/en
Priority to AU19286/00A priority patent/AU768535B2/en
Publication of WO2000033079A1 publication Critical patent/WO2000033079A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label

Definitions

  • This invention relates to nanoparticles having polymer shells attached to them, the polymer shells imparting one or more selected properties to the nanoparticles.
  • This invention also relates to a method of making the nanoparticles which utilizes a transition- metal, ring-opening metathesis polymerization of cyclic olefin derivatives, preferably norboraene derivatives, having a selected property. The method allows for the growth of the polymers off the surfaces of the nanoparticles.
  • the invention also relates to certain novel monomers and polymers and to methods and kits for the detection or quantitation of an analyte.
  • the invention provides a method of preparing nanoparticles having at least one polymer shell attached thereto, each polymer shell having a selected property or properties.
  • the method comprises attaching initiation monomers to the surfaces of the nanoparticles.
  • the nanoparticles having the initiation monomers attached to them are contacted with a transition metal, ring-opening, metathesis catalyst to activate the initiation monomers.
  • the nanoparticles are also contacted with one or more types of propagation monomers of the formula P-L-N under conditions effective so that the monomers are polymerized to form one or more polymer shells attached to the nanoparticles.
  • N is a cyclic olefin-containing group
  • P is a moiety which gives each polymer shell a selected property or properties
  • Lisa bond or linker The invention also provides the nanoparticles, the initiation monomers, and propagation monomers wherein P is a moiety having a property selected from the group consisting of redox activity, optical activity, electronic activity and magnetic activity.
  • the invention further provides a method for detecting or quantitating an analyte comprising contacting a type of the nanoparticles of the invention with a sample suspected of containing the analyte and detecting or measuring the property or properties of the nanoparticles in order to detect or quantitate the analyte.
  • the invention also provides a kit for detecting or quantitating an analyte comprising a container holding a type of the nanoparticles of the invention.
  • the invention provides a binding monomer.
  • the binding monomer has the formula N - L - B, wherein B is a binding moiety that binds specifically to an analyte, and N and L are defined above.
  • the invention also provides a polymer formed by polymerizing one or more types of the propagation monomers of the invention. These polymers may be used to detect or quantitate an analyte when L comprises a binding moiety B.
  • the invention also provides a method for detecting or quantitating an analyte comprising contacting a sample suspected of containing the analyte with the polymer and detecting or measuring the property or properties of the polymer in order to detect or quantitate the analyte.
  • the invention provides a kit for detecting or quantitating an analyte comprising a container holding a polymer of the invention wherein L comprises a binding moiety B.
  • the invention provides a method of detecting or quantitating an analyte comprising contacting the analyte with a type of binding monomers of the invention so that the binding monomers bind to the analyte. Then, a type of propagation monomers of the invention is added so that the propagation monomers polymerize to form a polymer attached to the analyte. Then, the property(ies) of the polymer attached to the analyte is(are) detected or measured in order to detect or quantitate the analyte.
  • the invention provides a kit for detecting or quantitating an analyte comprising a container holding a type of binding monomers of the invention, a container holding a type of propagation monomers of the invention, or both.
  • Figures 2A-H Figures 2A-E show the H NMR spectra of gold nanoparticles (GNPs) functionalized with a 3 : 1 mixture of 1 -dodecanethiol and 2 ( ⁇ 7 to 0 ppm) ( Figure 2A), GNPs functionalized with a 3 : 1 mixture of 1-dodecanethiol and 2 ( ⁇ 6.3 to 5.2 ppm) (Figure 2B), 2-modified GNPs after treatment with one equivalent of 1 ( ⁇ 6.3 to 5.2 ppm) ( Figure 2C), 2-modified GNPs after the addition of 20 equiv.
  • GNPs gold nanoparticles
  • FIG. 2F shows cyclic voltammetry of the GNP - poly 3 system ( Figure 2F), the GNP - poly 3 - poly 4 hybrid ( Figure 2G), and poly 3 ( Figure 2H). All cyclic voltammetry experiments utilized a gold working electrode, a platinum-gauze counter electrode, and a silver-wire reference electrode. Ferrocene (bis(cyclopentadienyl)iron) was used as an internal reference.
  • Figures 3A-B Transmission electron microscopy (TEM) images of 2- functionalized GNPs ( Figure 3 A) and GNP - poly 3 ( Figure 3B).
  • TEM Transmission electron microscopy
  • Figure 4 Diagram showing the structures of norbornenyl-containing monomers.
  • Figure 5A Diagram of an assay for the detection of nucleic acid (Target) using
  • Figure 5B Diagram of an assay for the detection of nucleic acid using a fluorescent norbornenyl-containing monomer.
  • Figure 6 Graphs of fluorescence emission versus wavelength for monomer 9 (graph A) and GNP - poly 9 (graph B).
  • Figures 7A-B Diagrams showing cross-linking of polymer-nanoparticle hybrids to produce nanoparticle polymer composites.
  • FIGS 8A-B Formulas of compounds 10-16.
  • Nanoparticles useful in the practice of the invention include metal (e.g., gold, silver, copper, and platinum), semiconductor (e.g., Si, CdSe, CdS, and CdS coated with metal (e.g., gold, silver, copper, and platinum), semiconductor (e.g., Si, CdSe, CdS, and CdS coated with metal (e.g., gold, silver, copper, and platinum), semiconductor (e.g., Si, CdSe, CdS, and CdS coated with metal (e.g., gold, silver, copper, and platinum), semiconductor (e.g., Si, CdSe, CdS, and CdS coated with metal (e.g., gold, silver, copper, and platinum), semiconductor (e.g., Si, CdSe, CdS, and CdS coated with metal (e.g., gold, silver, copper, and platinum), semiconductor (e.g., Si, CdSe, CdS, and CdS coated with metal (
  • ZnS zinc-silicon
  • polymer e.g., polystyrene and polymethylmethacrylate
  • magnetic e.g., ferromagnetite
  • insulator e.g., SiO 2
  • superconductor e.g., colloidal materials.
  • Other nanoparticles useful in the practice of the invention include ZnSe, ZnS, ZnO, TiO 2 , Agl, AgBr, Hgl 2 , PbS, PbSe, PbTe, ZnTe, SiO 2 , CdTe, In 2 S 3 , In 2 Se 3 , In 2 Te 3 , Cd 3 P 2 , Cd 3 As 2 , InAs, InP, GaP, and GaAs.
  • the size of the nanoparticles is preferably from about 1 nm to about 150 nm (mean diameter). More preferably the nanoparticles are from about 2 to about 100 nm. Most preferably the nanoparticles are from about 2 to about 30 nm.
  • Each nanoparticle will have a plurality of initiation monomers attached to it.
  • An "initiation monomer” is a compound comprising a functional group, which allows the initiation monomer to be attached to the nanoparticles, and a cyclic olefin group.
  • the cyclic olefin group is located on the initiation monomer so that, when the initiation monomer is attached to the nanoparticles, the olefin functionality will be accessible to participate in the polymerization of subsequently-added cyclic olefin-containing propagation monomers (described below).
  • the immobilized initiation monomers once activated by the addition of a suitable catalyst (described below), provide sites for the polymerization of the subsequently-added propagation monomers and allow for the selective growth of polymer blocks off the surfaces of the nanoparticles.
  • cyclic olefin means a compound containing 1-3 rings, each ring containing 3 or more carbon atoms, preferably 5-8 carbon atoms, and the compound further containing at least one carbon-carbon double bond in a ring (the "olefin functionality").
  • the cyclic olefin must be capable of undergoing ring-opening metathesis polymerization (ROMP).
  • ROMP ring-opening metathesis polymerization
  • a cyclic olefin is capable of undergoing ROMP when it contains sufficient strain in the ring(s) so that a ring-opening reaction will release the strain and provide the thermodynamic driving force for the formation of the polymer.
  • the cyclic olefin is norbornene, 7-oxonorbornene, cyclooctene, cyclooctadiene, cyclopentene, or cyclobutene. Most preferably, the cyclic olefin is norbornene.
  • attachment compounds Many compounds are known which can be attached to nanoparticles by means of a functional group (referred to hereinafter as "attachment compounds"). Methods of making these attachment compounds and attaching them to nanoparticles are well known.
  • the attachment compounds are stably attached to the surfaces of the nanoparticles by chemisorption of the molecules of the compound onto the nanoparticles or by covalent linkage of the molecules of the compound to the nanoparticles.
  • Suitable attachment compounds for use in the practice of the invention, and the corresponding type(s) of nanoparticles to which they attach include: a. Compounds ofthe formulaR ⁇ H, R X SSR 2 , R'SR 2 , R X NC, R X CN, R'CO.H, or ArSH can be attached to gold nanoparticles; b.
  • Compounds of formula R X SH, ArSH, or (R X ) 3 N can be attached to silver, copper, palladium, and semiconductor nanoparticles; c. Compounds of the formula R ⁇ C, R 2 SH, R ⁇ SR 2 , or R X SR 2 can be attached to platinum nanoparticles; d. Compounds of the formula R*SH can be attached to GaAs and InP nanoparticles; e. Organosilanes, including compounds of the formula R ⁇ iCl j and
  • Compounds of the formula R ⁇ OOH or R ⁇ ONHR 2 can be attached to metal oxide nanoparticles;
  • Compounds of the formula R ⁇ H, R 1 NH 2 , ArNH 2 , pyrrole, or pyrrole derivatives, wherein R 1 is attached to one ofthe carbons ofthe pyrrole ring, can be attached to cuprate high temperature superconductor nanoparticles;
  • Compounds of the formula R ⁇ OOH can be attached to aluminum, copper, silver, and platinum nanoparticles; and
  • Compounds that are unsaturated, such as azoalkanes (R 3 NNR 3 ) and isothiocyanates (R 3 NCS) can be attached to silicon nanoparticles.
  • R 1 and R 2 each has the formula X(CH 2 ) n and, if a compound is substituted with both R 1 and R 2 , R 1 and R 2 may be the same or different;
  • R 3 has the formula CH ⁇ CILJ,,; n is 0-30; Ar is an aryl; and
  • X is -CH 3 ,-CHCH 3 , -COOH, -CO 2 (CH 2 ) m CH 3 , -OH, -CH 2 OH, ethylene glycol, hexa(ethylene glycol), -O(CH 2 ) m CH 3 , -NH 2 , -NH(CH 2 ) m NH 2 , halogen, glucose, maltose, fullerene C60, a cyclic olefin, or a nucleic acid, where m is 0-30.
  • Suitable initiation monomers for use in the practice ofthe invention include cyclic olefin-containing derivatives of these known attachment compounds having the formula: N - L - A wherein:
  • N is a cyclic olefin-containing group
  • L is a bond or a linker whereby N is attached to A
  • A is an attachment compound-containing group.
  • the identity of A will depend on the identity of the material of which the nanoparticles are composed (see above).
  • L can be a linker.
  • L can be any desired chemical group.
  • L can be a polymer (e.g., polyethylene glycol, polymethylene, protein, peptide, oligonucleotide, or nucleic acid), — COO — , -CH 2 (CH 2 ) m COO-, -OCO-, -R ⁇ CH ⁇ -NR 1 -, -O(CH 2 ) m - -(CH 2 ) m -
  • L may also be or comprise a binding moiety B that binds specifically to an analyte (e.g., an antibody or oligonucleotide) (see below).
  • analyte e.g., an antibody or oligonucleotide
  • the initiation monomers can be synthesized by methods well known in the art.
  • the synthesis of the initiation monomers utilizes standard organic chemistry synthetic procedures whereby the cyclic olefin-containing group, N, and the attachment compound-containing group, A, are coupled to each other through a bond or are sequentially coupled to the linker, L.
  • the linker L. See, e.g., Larock, Comprehensive organic transformations : a guide to functional group preparations (VCH Publishers, New York, NY, 1989) and Comprehensive organic functional group transformations (Katritzky et al., eds., Pergamon Press, New York, 1995).
  • initiation monomers for use on a variety of nanoparticles are norbornenyl-containing alkanethiols.
  • Example 1 describes a method which can be used for the preparation of such initiation monomers.
  • the initiation monomers can be attached to the nanoparticles in the same manner as the attachment compounds are attached to nanoparticles. Such methods are well known in the art. See, e.g., the references cited in the above discussion of attachment compounds. Generally, the nanoparticles and the initiation monomers are simply brought into contact and allowed to remain in contact for a sufficient time so that initiation monomers attach to the nanoparticles. Preferably a mixture of initiation monomers and corresponding attachment compounds (as diluent) are attached to the nanoparticles to reduce crosslinking ofthe initiation monomers and the propagating polymer during the subsequent polymerization.
  • initiation monomer The ratio of initiation monomer to attachment compound that gives optimum results can be determined empirically and will depend on the type of initiation monomer, the type of attachment compound, and the type and size of the nanoparticles.
  • corresponding attachment compound is meant that the initiation monomers and attachment compounds are preferably, but not necessarily, ofthe same general type (e.g., alkanes) and preferably, but not necessarily, have the same functional group (e.g., thiol).
  • the catalyst is a transition metal ring-opening metathesis catalyst.
  • Many such catalysts suitable for use with cyclic olefin derivatives are known. See, e.g., U.S. Patents Nos. 4,250,063, 4,727,215, 4,883,851, 4,945,135, 4,945,141, 4,945,144, 5,146,033, 5, 198,511,
  • M may be osmium (Os) or ruthenium (Ru);
  • R 1 is hydrogen;
  • X 1 and X 2 may be different or the same and are any anionic ligand;
  • L 1 and L 2 may be different or the same and are any neutral electron donor; and
  • R 2 may be hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.
  • X 1 and X 2 are most preferably the same and are -Cl
  • L 1 and L 2 are preferably phosphines of the formula PhosR 3 R 4 R 5 , where Phos is phosphine, R 3 is a secondary alkyl or cycloalkyl, and R 4 and R 5 (which may be the same or different) are aryl, C,-C 10 primary alkyl, secondary alkyl, or cycloalkyl.
  • L 1 and L 2 are most preferably the same and are -Phos(cyclohexyl) 3 ,-Phos(cyclopentyl) 3 , or - Phos(isopropyl) 3 .
  • R 2 is hydrogen, C,-C 20 alkyl, or aryl.
  • the C J -C JO alkyl may optionally be substituted with one or more aryl, halide, hydroxy, C,-C 20 alkoxy, or C 2 -C 20 alkoxycarbonyl groups.
  • the aryl may optionally be substituted with one or more C r C 20 alkyl, aryl, hydroxyl, C,-C 5 alkoxy, amino, nitro, or halide groups.
  • the most preferred catalyst is compound 1 shown in Figure 1. The preparation of these catalysts and conditions for their use are described in Schwab et al, Angew. Chem. Int. Ed Engl, 34:2039 (1995), Lynn et al, J.
  • a family of catalysts comprising a rhenium (Nil) atom centrally linked to an alkylidene ligand (CR 1 ), an alkylidyne ligand (CHR 2 ), and two other ligands (R 3 and R 4 ), at least one of which is an electron withdrawing ligand which is sufficiently electron withdrawing to render the rhenium atom electrophilic enough for metathesis reactions.
  • the catalysts have the formula Re(CR x )(CHR 2 )(R 3 )(R 4 ).
  • R 1 is selected from the group consisting of an alkyl having 1-20 carbon atoms, an aryl having 6-20 carbon atoms, an araalkyl having 7-30 carbon atoms, halogen substituted derivatives of each, and silicon-containing analogs of each.
  • R 1 and R 2 examples include phenyl, t-butyl, trimethylsilyl, triphenyl, methyl, triphenylsilyl, tri-t-butyl, tri-t-butylsilyl, 2,6- diisopropylphenyl, 2,4,6-triisopropylphenyl, and2,6-dimethylphenyl
  • R 3 andR 4 canbeany group which is sufficiently electron withdrawing to render the rhenium atom electrophilic enough for metathesis reactions. While it is preferably that both R 3 and R 4 be electron withdrawing, the catalysts may contain only one electron withdrawing ligand.
  • R 3 and R 4 can be individually selected from groups consisting of R 1 , a halogen, triflate, and concatenated combinations of R 3 and R 4 , wherein R 3 and R 4 individually may contain alkoxide oxygen atoms which are bound to the rhenium atom, provided that when R 1 and R 2 are t-butyl and R 3 and R 4 are the same, then R 3 and R 4 are groups other than t- butoxide, trimethylsiloxide, neopentyl or a halogen.
  • R 3 and R 4 are both alkoxide ligands in which the alcohol corresponding to the electron withdrawing alkoxide ligands should have a pKa of about 9 or below.
  • Suitable ligands which fall within this range include phenoxide, hexafluoro-t-butoxide and diisopropylphenoxide.
  • Examples of concatenated R 3 and R 4 groups are pinacolate, 2,6-dimethyl-2,6-heptanediolate and propan-l,3-diolate.
  • the catalysts are typically monomers. However, they can form dimers, oligomers or polymers if the R 3 and R 4 groups are small enough to permit bridging of two or more metal centers.
  • An additional group of preferred catalysts are those having the formula: M(NR 1 )(OR 2 ) 2 (CHR 3 ).
  • M is molybdenum or tungsten;
  • R 1 and R 2 are alkyl, aryl, aralkyl, haloalkyl, haloaryl, haloaralkyl or a silicon-containing analog thereof;
  • the alkyls contain 1-20 carbon atoms, the aryls contain 6-20 carbon atoms, and the araalkyls contain 7-20 carbon atoms.
  • R 1 examples include 2,6-diisopropylphenyl, 2,4,6-trimethylphenyl, 2,6-di-t-butylphenyl, pentafluorophenyl, t- butyl, trimethylsilyl, triphenylmethyl, triphenylsilyl, tri-t-butylsilyl, and perfluoro-2-methyl-
  • R 2 examples include t-butyl, trifluoro-t-butyl, perfluoro-t-butyl, perfluoro-2- methyl-2-pentyl, 2,6-diisopropylphenyl, pentafluorophenyl, trimethylsilyl, triphenylsilyl, tri-t-butylsilyl, and hexafluoro-t-butyl
  • Patent No. 4,727,215 the complete disclosure of which is incorporated herein by reference.
  • the initiation monomers are activated with the catalyst by methods known in the art. See, e.g., those references cited above. Other suitable conditions and optimum conditions can be determined empirically.
  • the propagation monomers have the formula: N - L - P wherein:
  • N is a cyclic olefin-containing group
  • L is a bond or a linker whereby N is attached to P
  • P is any moiety which provides a selected property to the resulting polymer.
  • L is the same as described above for the initiation monomers.
  • P will impart a desired property to the resulting polymer and polymer-nanoparticle hybrids. Such properties include hydrophilicity, hydrophobicity, optical properties (e.g.
  • the property is an optical property or redox activity.
  • cyclic olefin-containing propagation monomers are known. See, e.g., U.S. Patents Nos. 4,250,063, 5,064,919, 5,117,327, 5,198,511, 5,200,470; Davies et al, J. Chem. Soc. Per/an I, 433 (1973); Posner et al, Tetrahedron, 32, 2281 (1976).
  • Other cyclic olefin-containing propagation monomers can be synthesized by standard organic chemistry synthetic procedures. In particular, the cyclic olefin moiety, N, and the moiety, P, are coupled to each other through a bond or are sequentially coupled to the linker, L, using well-known methods.
  • Suitable conditions for polymerizing the propagation monomers include those known in the art for polymerizing cyclic olefin and cyclic olefin derivatives. See, e.g., U.S. Patents Nos. 4,883,851, 4,945, 135, 4,945,141, 4,945,144, 5,198,511, 5,266,665, 5,296,437, 5,296,566, 5,312,940, 5,342,909, 5,728,785, 5,750,815, 5,831,108, 5,849,851, and references cited therein; Schwab et al, Angew. Chem. Int. Ed. Engl,
  • a single propagation monomer having a particular P group or a mixture of monomers having different P groups can be used to form a single polymer shell having a single or a plurality of properties.
  • polymerization of a single monomer or a mixture of monomers can be followed by polymerization of one or more additional monomers, together or singly, to form a plurality of polymer shells attached to the nanoparticles, each shell having a different property or properties.
  • the polymerization, and the resulting size(s) and properties ofthe polymer shell(s), can be controlled by suitable choices ofthe reaction conditions, including the catalyst, solvent, temperature, the type(s)of propagation monomer(s), the order of addition ofthe propagation monomer(s), and the amount(s) ofthe propagation monomer(s).
  • the polymerization is halted by the addition of a compound that terminates polymerization.
  • Suitable compounds are known in the art. See, e.g., those references cited above.
  • the polymer-nanoparticle hybrids of the invention have a variety of uses. For instance, they can be used as probes to detect or quantitate analytes. See, e.g., PCT application WO 98/04740; PCT application WO 98/21587; Storhoff et al, J. Clust. Sci., 8:179 (1997); Brousseau et al, J. Am. Chem. Soc, 120:7645 (1998); Freeman et al., Science, 267: 1629 (1995); Zhu et al, J. Am. Chem.
  • Analytes that can be detected or quantitated according to the invention include polysaccharides, lipids, lipopolysaccharides, proteins, glycoproteins, lipoproteins, nucleoproteins, peptides, oligonucleotides, and nucleic acids.
  • Specific analytes include antibodies, immunoglobulins, albumin, hemoglobin, coagulation factors, peptide and protein hormones (e.g., insulin, gonadotropin, somatotropin), non-peptide hormones, interleukins, interferons, other cytokines, peptides comprising a tumor-specific epitope (i.e., an epitope found only on a tumor-specific protein), cells (e.g., red blood cells), cell- surface molecules (e.g., CD antigens, integrins, cell receptors), microorganisms (viruses, bacteria, parasites, molds, and fungi), fragments, portions, components or products of microorganisms, small organic molecules (e.g., digoxin, heroin, cocaine, morphine, mescaline, lysergic acid, tetrahydrocannabinol, cannabinol, steroids, pentamidine, and biotin), etc. Nucleic acids and
  • DNA DNA, fungal DNA, mammalian DNA (e.g., human DNA), cDNA, mRNA, RNA and
  • DNA fragments DNA fragments, oligonucleotides, synthetic oligonucleotides, modified oligonucleotides, single-stranded and double-stranded nucleic acids, natural and synthetic nucleic acids, etc.
  • the polymer-nanoparticle hybrids must have a binding moiety, B, attached to them that allows the polymer-nanoparticle hybrids to bind specifically to the analyte.
  • Suitable binding moieties and methods of making them are well known in the art. For instance, essentially any analyte can be detected or quantitated using antibodies specific for the analyte. In addition, any molecule which binds specifically to the analyte can be used, and many such molecules are known in the art. For instance, nucleic acids can be detected or quantitated using oligonucleotides having a sequence which is complementary to at least a portion ofthe analyte nucleic acid.
  • lectins can be used to detect or quantitate polysaccharides and glycosylated proteins.
  • a receptor can be used to detect its ligand and vice versa.
  • binding moieties B are known.
  • the binding moiety B can be attached to the polymer-nanoparticle hybrids in a variety of ways.
  • the linker L ofthe initiation monomer or propagation monomer may be any desired chemical group.
  • the linker L in the propagation monomer and/or the initiation monomer may comprise a binding moiety B, such as a protein (e.g., antibody), an oligonucleotide, etc., and the binding moiety will be incorporated into the polymer shell(s) attached to the nanoparticles.
  • a binding moiety B such as a protein (e.g., antibody), an oligonucleotide, etc.
  • the binding moiety B such as a protein (e.g., antibody), an oligonucleotide, etc.
  • N is a cyclic olefin-containing group
  • L is a bond or a linker whereby N is attached to B;
  • L is the same as described above for the initiation monomers and propagation monomers. Preferably, however, L does not comprise a binding moiety B.
  • the binding monomers are synthesized and attached to the polymer-nanoparticle hybrids in the same manner as the propagation monomers.
  • the binding monomers or, preferably, a mixture of binding monomers and propagation monomers having a desired property or properties may be attached to the polymer-nanoparticle hybrids to form a final polymer shell on the nanoparticles.
  • the ratio of binding monomers to propagation monomers in such a mixture is preferably as low as possible. In this manner, even a single instance ofthe binding of B to its analyte can lead to a large detectable signal.
  • a sample suspected of containing an analyte is contacted with a type of polymer-nanoparticle hybrids having binding moieties B attached thereto.
  • a sample may be a biological fluid (e.g., serum, plasma, blood, saliva, and urine), cells, cell lysates, tissues, libraries of compounds (e.g., organic chemicals or peptides), solutions containing PCR components, etc.
  • Conditions and formats for performing such assays are well known in the art (see, e.g. , the references cited above) or can be determined empirically by those of ordinary skill in the art.
  • the property or properties ofthe polymer attached to the nanoparticles is
  • the property is redox activity or optical activity (e.g., fluorescence or color). Methods of detecting and measuring these properties are well known in the art.
  • FIG. 5A One format for detecting or quantitating nucleic acids is illustrated in Figure 5A.
  • capture oligonucleotides (Capture Strand) are attached to a gold substrate (e.g., a gold electrode).
  • a gold substrate e.g., a gold electrode.
  • Methods of attaching oligonucleotides to gold and other substrates are known. See, e.g., those references cited above describing functional groups, particularly PCT application WO 98/0470.
  • the capture oligonucleotides have a sequence complementary to at least a portion ofthe sequence of a nucleic acid analyte (Target), and the analyte nucleic acid is contacted with the substrate so that it binds to the capture oligonucleotides attached to the substrate.
  • polymer-nanoparticle hybrids having oligonucleotides attached to them are contacted with the analyte nucleic acid attached to the substrate.
  • the oligonucleotides on the polymer-nanoparticle hybrids have a sequence complementary to at least a portion ofthe sequence ofthe analyte nucleic acid and bind to the analyte nucleic acid attached to the substrate.
  • the property of the polymer attached to the nanoparticles is detected or measured.
  • the polymer is poly 3, a polymer which has redox activity, and this activity can be measured by cyclic voltammetry (see Example 1).
  • the invention further provides a kit for performing the assays for detecting or quantitating analytes.
  • the kit comprises a container holding polymer-nanoparticle hybrids having binding moieties, B, attached to them.
  • the kit may also contain other reagents and items useful for performing the assays.
  • the reagents may include controls, standards, PCR reagents, hybridization reagents, buffers, etc.
  • Other items which be provided as part of the kit include reaction devices (e.g., test tubes, microtiter plates, solid surfaces (possibly having a capture molecule attached thereto), syringes, pipettes, cuvettes, containers, etc.
  • the polymer-nanoparticle hybrids ofthe invention are also a new and versatile type of building block that chemists and material scientists can easily incorporate into many existing particle assembly strategies. See, e.g., PCT application WO 98/04740; Storhoff et al, J. Clust. Sci., 8:179 (1997).
  • the polymers could be reacted with a small amount of either a termination monomer or a propagation monomer containing a functional group so that at least some ofthe polymers on the nanoparticles would be capped with functional groups that would allow the polymer-nanoparticle hybrids to be attached to other nanoparticles (made of the same or a different material) or to solid substrates made of metal, magnetic or semiconductor materials (see above description ofthe materials from which the nanoparticles are made).
  • Termination monomers are the same as the initiation monomers described above, and the "functional groups” referred to in this paragraph are the same ones referred to in the discussion of initiation monomers.
  • novel cyclic olefin-containing monomers of the invention can also be polymerized alone (i.e., not attached to nanoparticles) in the same manner as described above.
  • Such polymers can be used in a variety of ways. For instance, polymers composed of propagation monomers wherein L comprises a binding moiety B (e.g., an oligonucleotide) can be used to detect and/or quantitate analytes by detection of the property or properties ofthe P groups.
  • the invention further provides a kit for performing the assays for detecting or quantitating analytes.
  • the kit comprises a container holding polymers formed from propagation monomers wherein L comprises a binding moiety B .
  • the kit may also contain other reagents and items useful for performing the assays.
  • propagation monomers wherein L comprises a binding moiety B can be used to detect and/or quantitate analytes by detection ofthe property or properties ofthe P groups.
  • a format useful for the detection or quantitation of nucleic acids is illustrated in Figure 5B.
  • a single strand of DNA, F is synthesized and modified at its 3' end to incorporate a functional group (e.g., an amino group) which is used for attachment ofthe DNA to a substrate (e.g., a transparent glass slide). See the discussion above of functional groups and their attachment to substrates.
  • the sequence of F is complementary to at least a portion ofthe sequence of a target DNA, F'-H-G'.
  • the G' sequence ofthe target DNA is complementary to a third DNA strand G which has been modified with a cyclic olefin-containing group (e.g. , as illustrated, a norbornene group, prepared using the phosphoramidite D).
  • a cyclic olefin-containing group e.g. , as illustrated, a norbornene group, prepared using the phosphoramidite D.
  • the substrate is then treated with a ROMP catalyst (e.g, catalyst 1, Figure 1), followed by exposure to a cyclic olefin-containing fluorescent monomer (e.g., norbornene-modified fluorescein monomer E in hexanes) to produce fluorescent polymers attached to the DNA attached to the substrate.
  • a cyclic olefin-containing fluorescent monomer e.g., norbornene-modified fluorescein monomer E in hexanes
  • the degree of polymerization on the substrate is dependent upon the reaction time, which is a tailorable quantity.
  • the fluorescence can be readily detected using a fluorescence microscope. This strategy allows for the high sensitivity and flexibility for DNA detection and quantitation for a number of reasons. First, any target can be detected as long as the sequences ofthe ends of the strand (F' and G') are known. Second, by using two shorter DNA strands, F and G, complementary to the target, the DNA synthetic chemistry becomes easier and more quantitative than using a longer strand (e.g., F-G or F-H-G).
  • this technique can be ultra-sensitive (i.e., capable of detecting sub-femtomolar levels of DNA).
  • propagation monomers comprising different binding moieties and/or having different properties can also be used in this format for the detection of DNA and other analytes.
  • the invention provides a kit for performing the assays for detecting or quantitating analytes.
  • the kit comprises a container holding propagation monomers wherein L comprises a binding moiety B.
  • the kit may also contain other reagents and items useful for performing the assays.
  • a type of refers to a plurality ofthe specified material having the same properties.
  • a type of nanoparticles refers to nanoparticles which are the same (e.g., gold nanoparticles of a particular size).
  • a type of polymer- nanoparticle hybrids having binding moieties B attached to them refers to a plurality of nanoparticles having the same polymer(s) and binding moieties attached to them.
  • This example describes the preparation of new metal-organic hybrid nanoparticles by the controlled growth of polymers from the surface of gold nanoparticle templates by ring-opening metathesis polymerization (ROMP) as illustrated in Figure 1.
  • ROMP ring-opening metathesis polymerization
  • a norbornenyl-terminated linear alkanethiol (2) is used to modify the surfaces of organic-soluble gold nanoparticles (GNPs).
  • a functional group tolerant ROMP catalyst (1) is used to initiate polymerization directly from the particle surface, after which a norbornenyl-containing monomer feedstock is injected into the solution with the initiated nanoparticles.
  • the first involves GNPs with a polymerized shell of a redox-active norbornenyl-functionalized ferrocene 3.
  • the second involves GNPs functionalized with an initial block of 3 followed by a second block of another redox-active norbornenyl-containing monomer 4.
  • the redox-potential of 4 is 220 mV more negative than that of 3, and the two can be easily differentiated by cyclic voltammetry.
  • 1 HNMR spectroscopy, cyclic voltammetry, and transmission electron microscopy ( Figures 2A-H and Figures 3A-B) have been used to characterize the polymerization process and the resulting polymer-modified nanoparticles.
  • Catalyst 1 was synthesized using published procedures. Schwab et al, Angew. Chem., Int. Ed. Engl, 34:2039 (1995); Lynn et al., J. Am. Chem. Soc, 120: 1627 (1998).
  • the dropping funnel was then replaced with a condenser, and the mixture was refluxed for an additional 12 hours under a positive stream of nitrogen.
  • the reaction mixture was poured into ether (50 mL) and washed successively with water (50 mL), 0.1 M NaOH (50 mL), and brine (50 mL).
  • the organic layer was collected, dried over sodium sulfate and filtered through a Buchner funnel. The solvent was removed on a rotary evaporator.
  • Ferrocenecarboxylic acid (0.511 g, 2.22 mmol) was weighed into a 100 mL Schlenk flask. The flask was placed under nitrogen using standard Schlenk techniques. Dry dichloromethane (50 mL) was added by cannula, and oxalyl chloride (0.291 mL, 3.34 mmol) was syringed into the reaction vessel . The mixture was stirred at room temperature for 2 hours. The solvent and excess oxalyl chloride were removed by rotary evaporation, and dry benzene (50 mL) was added by cannula.
  • ⁇ o-5-norbornen-2-ol (0.244 g, 2.22 mmol) was weighed into a 250 mL round-bottom flask and placed under nitrogen using standard Schlenk techniques. Dry benzene (50 mL) was added by cannula, and triethylamine (0.62 mL, 4.44 mmol) was syringed into the reaction vessel. The acid chloride solution in the Schlenk flask was then transferred into the round-bottom flask containing the alcohol solution by cannula, and the mixture was refluxed under nitrogen for 12 hours. The solution was diluted with brine (100 mL) and extracted with benzene (3 x 100 mL).
  • Ferroceneacetic acid (0.401 g, 1.64 mmol) was weighed into a 100 mL Schlenk flask. The flask was placed under nitrogen using standard Schlenk techniques. Dry dichloromethane (50 mL) was added by cannula, and oxalyl chloride (0.232 mL, 2.66 mmol) was syringed into the reaction vessel. The mixture was stirred at room temperature for 2 hours. The solvent and excess oxalyl chloride were removed by rotary evaporation, and dry benzene (50 mL) was added by cannula.
  • exo-5-norbornen-2-ol 0.181 g, 1.64 mmol
  • exo-5-norbornen-2-ol 0.181 g, 1.64 mmol
  • dry benzene 50 mL was added by cannula, and triethylamine (0.46 mL, 3.29 mmol) was syringed into the reaction vessel.
  • the acid chloride solution in the Schlenk flask was then transferred into the round-bottom flask containing the alcohol solution by cannula, and the mixture was refluxed under nitrogen for 12 hours.
  • the solution was diluted with brine (100 mL) and extracted with benzene (3 x 100 mL).
  • the benzene layers were combined, dried over magnesium sulfate, and the solvent was removed by rotary evaporation.
  • the benzene layers were passed through a short plug of silica gel (30 mm long, in a Pasteur pipette), and removal ofthe solvent on a rotary evaporator gave 0.281 g (0.84 mmol, 51%) ofthe desired product as a brown liquid.
  • the second key step in the preparation of metathesis-ready GNPs involves immobilization of 2 on 3 nm GNPs.
  • the method of Schiffrin (Brust et al, J. Chem. Soc, Chem. Commun., 801 (1994)) was modified for preparing 3 nm GNPs capped with linear alkanethiols by reducing HAuCl 4 (2.24 mmoles) in the presence of a 3:1 mixture of 1- dodecanethiol (1.68 mmoles), and 2 (0.56 mmoles) to yield GNPs modified with the two adsorbates.
  • the dodecanethiol diluent molecule was employed to minimize surface crosslinking of norbornenyl groups and propagating polymer.
  • the GNPs can be precipitated from CH 2 C1 2 by the addition of ethanol and redispersed in various organic solvents such as hexanes, ether, and CH 2 C1 2 .
  • the 1 HNMR spectrum ofthe modified particles in CDC1 3 confirms that the norbornene adsorbates are indeed attached to their surfaces, Figures 2A-B.
  • the two resonances at approximately ⁇ 5.9 and 6.2 are highly diagnostic ofthe two norbornenyl olefinic protons and compare well with those observed in the X HNMR spectrum of 2 ( ⁇ 5.9 and 6.2) in CDC1 3 .
  • the catalyst was quenched with ethyl vinyl ether (about 100 ⁇ L). Isolation ofthe particle-polymer hybrids (21 mg) was achieved by pouring the CDC1 3 solution into a vigorously stirring solution of hexanes (100 mL). The mother liquor was decanted, and the resulting dark brown precipitate was washed with hexanes
  • the GNP - poly 3 hybrids could be precipitated from CDC1 3 with hexanes, a solvent in which the 2-modified GNPs were completely redispersable. Once washed thoroughly with hexanes, the GNP - poly 3 hybrids could be redispersed in a variety of more polar organic solvents, such as CH 2 C1 2 and THF. These solubility properties mirror those of the untethered ferrocenyl homopolymer, which was independently synthesized from 1 and 3 under nearly identical conditions (poly 3; see below).
  • block copolymers of two different norbornenyl ferrocenyl derivatives, 3 and 4 were grown successively from the surfaces of 2-modified particles treated with catalyst 1.
  • 3 nm GNPs modified with 2 (10 mg) were weighed into a screw-top NMR tube, and 100 ⁇ L of CDC1 3 was added.
  • Catalyst 1 (1 equivalent, 1.5 mg, 1.8 ⁇ mol) was dissolved in 200 ⁇ L of CDCL, and syringed into the NMR tube containing the 2-modified GNPs. The NMR tube was capped and placed on a shaker for 10 minutes.
  • this methylene group provides a spectroscopic tag that allows allows one to follow the polymerization reaction by 1 HNMR, Figure 2E (note the asterisked resonance).
  • E 1/2s -40 mV for the block of poly 4 and 180 mN for the block of poly 3 vs FcH/FcH + )
  • Figure 2G A comparison ofthe integrated current associated with these two waves allows one to evaluate the relative amounts of 3 and 4 in the G ⁇ P - poly 3 - poly 4 structure. Based on this analysis, a 1.4:1 ratio was calculated for 3 and 4 in the block copolymer.
  • Example 4 This example describes the preparation of compound 7 (see Figure 4).
  • 2-norbornene-5-exo-acetic acid 450 mg, 3.0 mmol.
  • the flask was placed under nitrogen using standard Schlenk techniques.
  • Dry CH 2 C1 2 (20 mL) was added by cannula, followed by oxalyl chloride (5 mL of a 2 M solution in CH 2 C1 2 , 10 mmol).
  • the mixture was allowed to stir for 2 hours at room temperature.
  • the solvent and excess oxalyl chloride were removed under vacuum and the resulting acid chloride was redissolved in dry diethyl ether (20 mL).
  • Monomers such as 5, 7, and 8 are doubly polymerizable monomers that can undergo ROMP chemistry followed by a second cross-linking reaction to give a conducting graft copolymer composite. With these new monomers, new nanoparticles/conducting polymer composites can be made (see Figures 7A-B).
  • This example describes the synthesis of exo-5-norbornen-2-yl pyrenecarboxylate (compound 9 in Figure 4).
  • Pyrenecarboxylic acid 0.547 g, 2.22 mmol
  • the flask was placed under nitrogen using standard Schlenk techniques.
  • Dry dichloromethane 50 mL was added by cannula, and oxalyl chloride (0.291 mL, 3.34 mmol) was syringed into the reaction vessel. The mixture was stirred at room temperature for 2 hours.
  • Compound 9 is fluorescent, and the fluorescence emission spectra ofthe monomer and of poly 9 are shown in Figure 6. As expected, the fluorescence of poly 9 occurs at a lower wavelength, and is broader and less intense, than that of monomer 9 itself. These behaviors suggest the formation of intramolecular excimers in poly 9 due to the close proximity ofthe chromophores.
  • Example 8 This example describes the synthesis of N- ⁇ -(N, N-dimethylammonium- methylferrocenebromide)-a'-(exo-5-norbornene-2-ol)-p-xylene (11) (see Figure 8A).
  • 10 293 mg, 1.00 mmol
  • anhydrous diethyl ether 25 mL
  • a magnetic stirring bar 25 mL
  • a solution ofN, N-dimethylaminomethylferrocene 243 mg, 1.00 mmol
  • the mixture was stirred for 6 hours, during which time a yellow precipitate formed.
  • This example describes a general polymerization procedure for 10 or 11. Polymerization of 11 is described.
  • 11 110 mg, 0.21 mmol
  • MeOH a solution of catalyst 1 (7.0 mg, 0.0085 mmol, 4 mole %) in dry CH 2 C1 2 (0.5 mL).
  • the mixture was stirred for 30 minutes, after which time it was removed from the dry box and the polymerization was terminated with ethyl vinyl ether (1 mL).
  • the polymer (ROMP-polyll, 101 mg, 92%) was isolated by pouring the mixture into anhydrous diethyl ether ( 100 mL) and repeatedly filtering and washing with fresh diethyl ether (4 x 50 mL).
  • This example describes the synthesis of 12-14 (see Figure 8A).
  • the synthesis of 12 is representative.
  • a mixture of 10 (440 mg, 1.5 mmol) and 9-NN-dimethyl- aminomethylanthracene (235 mg, 1.0 mmol) inDMF (25 mL) was refluxed for 16 hours. After this time, the mixture was poured into diethyl ether (250 mL). The yellow solid which precipitated from solution was filtered and washed successively with diethyl ether (4 x 50 mL) to yield the desired product 12 (432 mg, 0.82 mmol, 82 %).
  • Example 12 This example describes the synthesis of 16 (see Figure 8B). Amixture of 10 (1.40 g, 4.77 mmol), fluorescein (800 mg, 2.40 mmol), and potassium carbonate (665 mg, 4.80 mmol) in acetone (25 mL) was refluxed for 36 hours. After this time, the mixture was poured into ice water (100 mL), filtered, and washed with water (400 mL). Recrystalization from DMF with acidic water yielded the desired product 16 (727 mg, 0.96 mmol, 40 %).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Composite Materials (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
  • Polymerisation Methods In General (AREA)
PCT/US1999/028387 1998-11-30 1999-11-30 Nanoparticles with polymer shells WO2000033079A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP99962951A EP1135682B1 (en) 1998-11-30 1999-11-30 Nanoparticles with polymer shells
DE69936534T DE69936534T2 (de) 1998-11-30 1999-11-30 Nanopartikel mit polymerschalen
JP2000585664A JP3650582B2 (ja) 1998-11-30 1999-11-30 ポリマー−ナノ粒子ハイブリッド粒子
US09/830,620 US7115688B1 (en) 1998-11-30 1999-11-30 Nanoparticles with polymer shells
CA002352362A CA2352362C (en) 1998-11-30 1999-11-30 Nanoparticles with polymer shells
AU19286/00A AU768535B2 (en) 1998-11-30 1999-11-30 Nanoparticles with polymer shells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11032798P 1998-11-30 1998-11-30
US60/110,327 1998-11-30

Publications (1)

Publication Number Publication Date
WO2000033079A1 true WO2000033079A1 (en) 2000-06-08

Family

ID=22332416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028387 WO2000033079A1 (en) 1998-11-30 1999-11-30 Nanoparticles with polymer shells

Country Status (9)

Country Link
US (1) US7115688B1 (zh)
EP (2) EP2000803A1 (zh)
JP (1) JP3650582B2 (zh)
CN (2) CN100406890C (zh)
AT (1) ATE366932T1 (zh)
AU (1) AU768535B2 (zh)
CA (1) CA2352362C (zh)
DE (1) DE69936534T2 (zh)
WO (1) WO2000033079A1 (zh)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060969A1 (en) * 2000-02-18 2001-08-23 Biophan, Llc Hybrid nucleic acid assembly
WO2002044725A1 (en) * 2000-11-30 2002-06-06 Innotrac Diagnostics Oy Bioanalytical assay
WO2002096262A3 (en) * 2001-05-25 2003-02-20 Univ Northwestern Non-alloying core shell nanoparticles
WO2002063304A3 (de) * 2001-02-08 2003-03-13 Ibidi Gmbh Probenträger für chemische und biologische proben
US6541617B1 (en) 1998-10-27 2003-04-01 Clinical Micro Sensors, Inc. Detection of target analytes using particles and electrodes
WO2003031561A1 (en) * 2001-10-10 2003-04-17 Biomed Solutions, Llc Hybrid nucleic acid assembly
US6602669B2 (en) 2000-07-11 2003-08-05 Northwestern University Method of detection by enhancement of silver staining
DE10203907A1 (de) * 2002-01-31 2003-08-21 Karlsruhe Forschzent Fluoreszierende Nanoteilchen und deren Herstellung
WO2003087188A1 (en) * 2001-04-26 2003-10-23 Nanosphere, Inc. Oligonucleotide-modified romp polymers and co-polymers
US6645721B2 (en) 1996-07-29 2003-11-11 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6673548B2 (en) 1996-07-29 2004-01-06 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6726847B2 (en) 2000-12-06 2004-04-27 Northwestern University Silver stain removal by chemical etching and sonication
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6767702B2 (en) 1996-07-29 2004-07-27 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6773884B2 (en) 1996-07-29 2004-08-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6812334B1 (en) 1996-07-29 2004-11-02 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
EP1496363A4 (en) * 2002-04-03 2005-05-18 Japan Science & Tech Agency SENSOR SIDE FOR BIOPUCE CARRIER OF NANOPARTICLES OF POLYETHYLENE GLYCOLATE
JP2005513999A (ja) * 2000-11-15 2005-05-19 ミナーヴァ・バイオテクノロジーズ・コーポレーション オリゴヌクレオチド識別子
US6908737B2 (en) 1999-04-15 2005-06-21 Vitra Bioscience, Inc. Systems and methods of conducting multiplexed experiments
EP1439391A3 (en) * 2003-01-15 2005-07-27 Agilent Technologies, Inc. Biosensor systems and methods for determining the presence of biomolecules
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US6984491B2 (en) 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2004111602A3 (en) * 2003-05-16 2006-09-28 Univ Rochester Colorimetric and fluorescent methods for sensing of oligonucleotides
US7115688B1 (en) 1998-11-30 2006-10-03 Nanosphere, Inc. Nanoparticles with polymer shells
US7147687B2 (en) 2001-05-25 2006-12-12 Nanosphere, Inc. Non-alloying core shell nanoparticles
US7169556B2 (en) 1996-07-29 2007-01-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7186814B2 (en) 2001-11-09 2007-03-06 Nanosphere, Inc. Bioconjugate-nanoparticle probes
WO2007065120A3 (en) * 2005-12-02 2007-08-02 Mark Lelental Ultransensitive chemically amplified bioanalytical assays
US7253435B2 (en) 1999-04-15 2007-08-07 Millipore Corporation Particles with light-polarizing codes
US7253277B2 (en) 2002-07-02 2007-08-07 Nanosphere, Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
EP1624306A4 (en) * 2003-04-30 2008-12-24 Chengdu Kuachang Medical Ind L DEVICE CONTAINING THE NANOSTRUCTURES USED FOR SEPARATION OR ANALYSIS AND MANUFACTURE AND APPLICATION THEREOF
US7488451B2 (en) 2003-09-15 2009-02-10 Millipore Corporation Systems for particle manipulation
US7557070B2 (en) 2000-10-18 2009-07-07 Millipore Corporation Multiplexed cell analysis system
KR100969086B1 (ko) 2001-10-10 2010-07-09 제이에스알 가부시끼가이샤 노르보르넨 유도체 및 그의 노르보르넨계 개환 중합체
US7766993B2 (en) 2004-09-10 2010-08-03 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7985539B2 (en) 2002-05-07 2011-07-26 Northwestern University Nanoparticle probes with raman spectroscopic fingerprints for analyte detection
EP3449945A4 (en) * 2016-08-05 2020-06-10 Shenzhen Profound-View Pharma Tech Co., Ltd. SUBSTANCE WITH GOLD CLUSTER AND PRODUCTION METHOD AND USE THEREOF

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096321A1 (en) * 1999-05-19 2003-05-22 Jose Remacle Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
JP3728411B2 (ja) * 2001-09-18 2005-12-21 ソニー株式会社 磁性粒子の作製方法、磁性粒子および磁性材料
US7825200B2 (en) * 2003-02-28 2010-11-02 The Regents Of The University Of California Controlled free radical grafting from polyolefins
CN1297253C (zh) * 2004-06-15 2007-01-31 复旦大学 一种可脑内递药的药物传递系统
FR2871701B1 (fr) * 2004-06-21 2006-09-22 Centre Nat Rech Scient Cnrse Biomateriaux bioactifs pour le relarguage controle de principes actifs
WO2006038420A1 (ja) * 2004-09-30 2006-04-13 Kaneka Corporation ポリマー修飾金属カルコゲン化物ナノ粒子の製造方法
BRPI0711203A2 (pt) * 2006-05-22 2011-03-22 Nanomech Llc nano/micropartìculas não metálicas revestidas com metal seus processos e aplicações
US8481161B2 (en) * 2006-06-28 2013-07-09 Samsung Electronics Co., Ltd. Functionalized metal nanoparticle and method for formation of conductive pattern using the same
US8778846B2 (en) * 2006-12-04 2014-07-15 General Electric Company Composition, device and associated method
EP2140264A1 (en) * 2007-04-19 2010-01-06 3M Innovative Properties Company Methods of use of solid support material for binding biomolecules
EP2137533A2 (en) * 2007-04-19 2009-12-30 3M Innovative Properties Company Uses of water-dispersible silica nanoparticles for attaching biomolecules
US8268638B2 (en) 2007-07-18 2012-09-18 Advantageous Systems, Llc Methods and apparatuses for detecting analytes in biological fluid of an animal
WO2009145813A1 (en) 2008-03-04 2009-12-03 Qd Vision, Inc. Particles including nanoparticles, uses thereof, and methods
KR101462653B1 (ko) * 2008-05-20 2014-11-17 삼성전자 주식회사 카르벤 유도체를 이용한 나노입자 제조방법
DE102009015470A1 (de) * 2008-12-12 2010-06-17 Byk-Chemie Gmbh Verfahren zur Herstellung von Metallnanopartikeln und auf diese Weise erhaltene Metallnanopartikel und ihre Verwendung
CN102449010B (zh) * 2009-04-10 2014-06-18 伦斯勒理工学院 用于电绝缘体的被二嵌段共聚物改性的纳米粒子-聚合物纳米复合物
EP2246376B1 (en) 2009-04-27 2014-03-05 Leibniz-Institut für Polymerforschung Dresden e.V. Method for preparing particles with a conjugated polymer shell
US8268359B2 (en) * 2009-08-26 2012-09-18 Indian Institute Of Technology Madras Organic polymer-inorganic fine particle antimicrobial composites and uses thereof
CN102482457B (zh) 2009-09-09 2015-04-15 Qd视光有限公司 包含纳米颗粒的颗粒、其应用和方法
WO2011031876A1 (en) 2009-09-09 2011-03-17 Qd Vision, Inc. Formulations including nanoparticles
WO2012134629A1 (en) 2011-04-01 2012-10-04 Qd Vision, Inc. Quantum dots, method, and devices
US8591759B2 (en) * 2011-05-31 2013-11-26 Chemgreen Innovation Inc. Magnetic nanocomposite material and processes for the production thereof
SG2014014344A (en) * 2011-09-23 2014-06-27 Univ Nanyang Tech Methods for forming gold nanowires on a substrate and gold nanowires formed thereof
EP2636693A1 (en) 2012-03-09 2013-09-11 Universitätsklinikum Freiburg Synthesis and micro-/nanostructuring of surface-attached crosslinked antimicrobial and/or antibiofouling polymer networks
US9512468B2 (en) 2012-11-06 2016-12-06 Industrial Technology Research Institute Detection method uses magnetic and detectable nanoparticles with oligonucleotides attached thereto
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
DE102013106432A1 (de) * 2013-06-20 2014-12-24 Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG Optische Indikator-Einheit und Vorrichtung und Verfahren zur Bestimmung einer physikalisch-chemischen Eigenschaft eines Prozessmediums in einer prozesstechnischen Anlage
JP6360345B2 (ja) * 2014-04-22 2018-07-18 五稜化薬株式会社 キサンテン化合物及びその用途
WO2017041061A1 (en) * 2015-09-04 2017-03-09 Massachusetts Institute Of Technology Synthesis of nanocrystals
BR112019003709A2 (pt) 2016-08-25 2019-05-28 Centre Nat Rech Scient nanopartículas de silício multifuncionalizadas, usos de nanopartículas de silício multifuncionalizadas, composição e métodos para medir um analito por um método in vitro
US20190292310A1 (en) * 2018-03-20 2019-09-26 Northeastern University Synthesis of high density molecular dna brushes via organic-phase ring-opening metathesis (co)polymerization
CN108997520B (zh) * 2018-06-07 2020-07-28 上海应用技术大学 一种降冰片烯衍生物含异类糖单元均聚物及其合成方法
CN113646633A (zh) * 2018-10-17 2021-11-12 易兹代亚科技股份有限公司 生物材料侦测微颗粒和使用其的生物材料侦测方法
CN111229169A (zh) * 2018-11-29 2020-06-05 天津大学 蛋白功能化磁性复合材料及其制备方法和应用
CN114522728B (zh) * 2020-11-04 2024-04-19 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 一种二茂铁功能化的纳米催化剂及其制备方法与应用
CN112067647B (zh) * 2020-11-11 2021-01-15 东南大学 一种检测液体生物样本葡萄糖含量的弛豫核磁共振方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4023981A (en) * 1974-06-14 1977-05-17 Produits Chimiques Ugine Kuhlmann Process for the preparation of pigmentary metallic particles coated with an organic polymer and compositions resulting therefrom
US4454234A (en) * 1981-12-30 1984-06-12 Czerlinski George H Coated magnetizable microparticles, reversible suspensions thereof, and processes relating thereto
US4846893A (en) * 1987-02-04 1989-07-11 Fuji Xerox Co., Ltd. Process for producing a surface treated pigment
US5053471A (en) * 1987-11-17 1991-10-01 Japan Synthetic Rubber Co., Ltd. Transparent resin material
US5342909A (en) * 1992-04-03 1994-08-30 California Institute Of Technology Ruthenium and osmium metal carbene complexes for olefin metathesis polymerization
US5639620A (en) * 1990-10-31 1997-06-17 Coulter Corporation Polymeric particles having a biodegradable gelatin or aminodextran coating and process for making same
US5736413A (en) * 1989-11-17 1998-04-07 Laboratoires Merck Clevenot Immunodiagnostic reagent for carrying out a multi-stage immunoassay of at least one biological substance in a plurality of biological samples
US5766764A (en) * 1996-06-04 1998-06-16 The Boeing Company Nanoscale amorphous magnetic metals

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193983A (en) 1978-05-16 1980-03-18 Syva Company Labeled liposome particle compositions and immunoassays therewith
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
US4318707A (en) 1978-11-24 1982-03-09 Syva Company Macromolecular fluorescent quencher particle in specific receptor assays
US4256834A (en) 1979-04-09 1981-03-17 Syva Company Fluorescent scavenger particle immunoassay
US4261968A (en) 1979-05-10 1981-04-14 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4650770A (en) 1981-04-27 1987-03-17 Syntex (U.S.A.) Inc. Energy absorbing particle quenching in light emitting competitive protein binding assays
US4713348A (en) 1983-04-05 1987-12-15 Syntex (U.S.A.) Inc. Fluorescent multiparameter particle analysis
US5288609A (en) 1984-04-27 1994-02-22 Enzo Diagnostics, Inc. Capture sandwich hybridization method and composition
US4868104A (en) 1985-09-06 1989-09-19 Syntex (U.S.A.) Inc. Homogeneous assay for specific polynucleotides
US4996143A (en) 1985-12-23 1991-02-26 Syngene, Inc. Fluorescent stokes shift probes for polynucleotide hybridization
US5137827A (en) 1986-03-25 1992-08-11 Midwest Research Technologies, Inc. Diagnostic element for electrical detection of a binding reaction
US5514602A (en) 1986-06-09 1996-05-07 Ortho Diagnostic Systems, Inc. Method of producing a metal sol reagent containing colloidal metal particles
US5360895A (en) 1987-04-22 1994-11-01 Associated Universities, Inc. Derivatized gold clusters and antibody-gold cluster conjugates
US4853335A (en) 1987-09-28 1989-08-01 Olsen Duane A Colloidal gold particle concentration immunoassay
GB8800702D0 (en) 1988-01-13 1988-02-10 Nycomed As Test method & reagent kit therefor
WO1990002205A1 (en) 1988-08-25 1990-03-08 Angenics, Inc. Detection of nucleic acid sequences using particle agglutination
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
GB9019512D0 (en) 1990-09-06 1990-10-24 Ici Plc Assay method
US5665582A (en) 1990-10-29 1997-09-09 Dekalb Genetics Corp. Isolation of biological materials
WO1992008133A1 (en) 1990-10-29 1992-05-14 Dekalb Plant Genetics Isolation of biological materials using magnetic particles
US5294369A (en) 1990-12-05 1994-03-15 Akzo N.V. Ligand gold bonding
ES2034891B1 (es) 1991-08-08 1993-12-16 Cusi Lab Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
EP0613585A4 (en) 1991-11-22 1995-06-21 Univ California SEMICONDUCTING NANOCRYSTALS CONNECTED TO SOLID INORGANIC SURFACES BY SELF-ASSEMBLED SINGLE LAYERS.
US5225064A (en) 1992-01-15 1993-07-06 Enzyme Technology Research Group, Inc. Peroxidase colloidal gold oxidase biosensors for mediatorless glucose determination
WO1996004289A1 (en) 1992-04-03 1996-02-15 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5710298A (en) 1992-04-03 1998-01-20 California Institute Of Technology Method of preparing ruthenium and osmium carbene complexes
GB9212164D0 (en) 1992-06-09 1992-07-22 Medical Res Council Preparation of nucleic acids
US5472881A (en) 1992-11-12 1995-12-05 University Of Utah Research Foundation Thiol labeling of DNA for attachment to gold surfaces
US5637508A (en) 1993-03-26 1997-06-10 Geo-Centers, Inc. Biomolecules bound to polymer or copolymer coated catalytic inorganic particles, immunoassays using the same and kits containing the same
US5384265A (en) 1993-03-26 1995-01-24 Geo-Centers, Inc. Biomolecules bound to catalytic inorganic particles, immunoassays using the same
FR2703359B1 (fr) 1993-03-31 1995-06-23 Cis Bio Int Copolymère nucléotide(s)/polymère conducteur électronique ; son procédé de préparation et son utilisation .
US5681943A (en) 1993-04-12 1997-10-28 Northwestern University Method for covalently linking adjacent oligonucleotides
US5512635A (en) 1993-05-27 1996-04-30 Amoco Corporation Process for preparing linear monofunctional and telechelic difunctional polymers and compositions obtained thereby
JPH08511425A (ja) 1993-06-09 1996-12-03 ガメラ バイオサイエンス コーポレイション 磁気サイクル反応
EP0630974A3 (en) 1993-06-25 1995-11-15 Clinical Diagnostic Syst Method and test kit for the detection of inorganic orthophosphate in the amplification of target nucleic acids.
EP0706709A1 (en) * 1993-06-30 1996-04-17 Carnegie Mellon University Metal, alloy, or metal carbide nanoparticles and a process for forming same
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5468819A (en) 1993-11-16 1995-11-21 The B.F. Goodrich Company Process for making polymers containing a norbornene repeating unit by addition polymerization using an organo (nickel or palladium) complex
US5639900A (en) 1993-12-29 1997-06-17 Metton America, Inc. Thermally activated olefin metathesis catalyst precursor
JPH07227299A (ja) 1994-02-14 1995-08-29 Kyoto Daiichi Kagaku:Kk Ｄｎａの特定塩基配列の検出方法及びその装置
ES2078190B1 (es) * 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
JPH10502691A (ja) 1994-07-08 1998-03-10 ミネソタ マイニング アンド マニュファクチャリング カンパニー 過圧反応
US5521289A (en) 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US5599668A (en) 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
US5634620A (en) * 1994-11-10 1997-06-03 Verot; Thierry R. E. Clamp assembly for motor flushing device
US5747248A (en) 1994-12-05 1998-05-05 Chiron Corporation Discontinuous probe design using hybritope mapping
US6025202A (en) 1995-02-09 2000-02-15 The Penn State Research Foundation Self-assembled metal colloid monolayers and detection methods therewith
US5609907A (en) 1995-02-09 1997-03-11 The Penn State Research Foundation Self-assembled metal colloid monolayers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5840820A (en) 1995-04-13 1998-11-24 The University Of North Carolina At Chapel Hill Olefin metathesis reactions in carbon dioxide medium
US5677405A (en) 1995-05-24 1997-10-14 The B.F. Goodrich Company Homopolymers and copolymers of cationically polymerizable monomers and method of their preparation
US6509459B1 (en) 1995-06-01 2003-01-21 Hybridon, Inc. Base protecting groups and rapid process for oligonucleotide synthesis
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
JPH11509585A (ja) 1995-06-23 1999-08-24 ミネソタ マイニング アンド マニュファクチャリング カンパニー 支持体に持続的な撥液性を付与するための組成物および方法
US5728785A (en) 1995-07-07 1998-03-17 California Institute Of Technology Romp polymerization in the presence of peroxide crosslinking agents to form high-density crosslinked polymers
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DE19527124A1 (de) 1995-07-25 1997-01-30 Henkel Kgaa Oxidationsfärbemittel
US5831108A (en) 1995-08-03 1998-11-03 California Institute Of Technology High metathesis activity ruthenium and osmium metal carbene complexes
US5939504A (en) 1995-12-07 1999-08-17 Advanced Polymer Technologies Method for extending the pot life of an olefin metathesis polymerization reaction
US6020443A (en) 1996-02-08 2000-02-01 Advanced Polymer Technologies, Inc. Polymerization of low grade DCPD monomers using an olefin metathesis catalyst
IL126544A (en) 1996-04-25 2004-08-31 Genicon Sciences Inc Analyte assay using scattered-light detectable particles
US6586193B2 (en) 1996-04-25 2003-07-01 Genicon Sciences Corporation Analyte assay using particulate labels
US6156692A (en) 1996-04-30 2000-12-05 Bp Amoco Corporation Ruthenium-containing catalyst composition for olefin metathesis
US6159890A (en) 1996-04-30 2000-12-12 Bp Amoco Corporation Ruthenium-containing catalyst system for olefin metathesis
FR2750136B1 (fr) 1996-06-25 1998-08-14 Cis Bio Int Conjugues d'un oligonucleotide/polymere conducteur electronique avec une molecule d'interet, et leurs utilisations
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7169556B2 (en) 1996-07-29 2007-01-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6984491B2 (en) 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6767702B2 (en) 1996-07-29 2004-07-27 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
DE69737598T2 (de) 1996-07-29 2007-12-27 Nanosphere Inc., Skokie Nanopartikel mit daran angehefteten oligonukleotiden sowie deren verwendungen
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6060570A (en) 1996-08-12 2000-05-09 Bp Amoco Corporation Process for preparation of addition products of difunctional telechelic polyolefins from cyclic olefins by olefin metathesis reaction
WO1998010289A1 (en) 1996-09-04 1998-03-12 The Penn State Research Foundation Self-assembled metal colloid monolayers
CA2269444A1 (en) 1996-10-23 1998-04-30 Skw Trostberg Aktiengesellschaft Process for producing biologically active polymer nanoparticle-nucleic acid conjugates
US5830986A (en) 1996-10-28 1998-11-03 Massachusetts Institute Of Technology Methods for the synthesis of functionalizable poly(ethylene oxide) star macromolecules
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US5922537A (en) 1996-11-08 1999-07-13 N.o slashed.AB Immunoassay, Inc. Nanoparticles biosensor
US5917071A (en) 1996-11-15 1999-06-29 California Institute Of Technology Synthesis of ruthenium or osmium metathesis catalysts
US6310121B1 (en) 1996-12-02 2001-10-30 Cymetech, Llc Polymeric composites including dicyclopentadiene and related monomers
US5760126A (en) 1996-12-20 1998-06-02 Minnesota Mining And Manufacturing Company Aqueous fluorochemical compositions and abrasion-resistant coatings therefrom
US6080826A (en) 1997-01-06 2000-06-27 California Institute Of Technology Template-directed ring-closing metathesis and ring-opening metathesis polymerization of functionalized dienes
US5939021A (en) 1997-01-23 1999-08-17 Hansen; W. Peter Homogeneous binding assay
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
US5916983A (en) 1997-05-27 1999-06-29 Bend Research, Inc. Biologically active compounds by catalytic olefin metathesis
US6107237A (en) 1997-07-10 2000-08-22 University Of Florida Homogeneous metathesis/heterogeneous hydrogenation
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
DE19736609A1 (de) 1997-08-22 1999-02-25 Basf Ag Verfahren zur Herstellung von Rutheniumkomplexen
US5808126A (en) 1997-09-03 1998-09-15 Dow Corning Corporation Synthesis of functional silyl terminated branched polyalkenylenes and polyolefins
CA2246155A1 (en) 1997-09-05 1999-03-05 Michael A. Giardello Metathesis polymerized olefin articles containing flame-retarding agents
US6040363A (en) 1997-09-05 2000-03-21 A. O. Smith Corporation Metathesis polymerizered olefin composites including sized reinforcement material
AUPP004497A0 (en) 1997-10-28 1997-11-20 University Of Melbourne, The Stabilized particles
US6149868A (en) 1997-10-28 2000-11-21 The Penn State Research Foundation Surface enhanced raman scattering from metal nanoparticle-analyte-noble metal substrate sandwiches
US6284852B1 (en) 1997-10-30 2001-09-04 California Institute Of Technology Acid activation of ruthenium metathesis catalysts and living ROMP metathesis polymerization in water
AU1450699A (en) 1997-10-31 1999-05-24 Gen-Probe Incorporated Methods of nucleic acid detection
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5972615A (en) 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6121473A (en) 1998-02-19 2000-09-19 Massachusetts Institute Of Technology Asymmetric ring-closing metathesis reactions
US6288197B1 (en) 1998-04-27 2001-09-11 The University Of Akron Supramolecular structures and process for making the same
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6290839B1 (en) 1998-06-23 2001-09-18 Clinical Micro Sensors, Inc. Systems for electrophoretic transport and detection of analytes
US6346652B1 (en) 1998-07-13 2002-02-12 Massachusetts Institute Of Technology Asymmetric ring-closing metathesis reactions involving achiral and meso substrates
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6107420A (en) 1998-07-31 2000-08-22 California Institute Of Technology Thermally initiated polymerization of olefins using Ruthenium or osmium vinylidene complexes
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6203989B1 (en) 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
IL126776A (en) 1998-10-27 2001-04-30 Technion Res & Dev Foundation A method of investing gold
EP2000803A1 (en) 1998-11-30 2008-12-10 Nanosphere, Inc. Nanoparticles with Polymer Shells
US6277489B1 (en) 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
US6342621B1 (en) 1999-01-29 2002-01-29 Nippon Zeon Co., Ltd. Ruthenium catalysts for metathesis reactions of olefins
US6225488B1 (en) 1999-04-02 2001-05-01 Nippon Zeon Co., Ltd. Ruthenium or osmium catalysts for olefin metathesis reactions
US6271315B1 (en) 1999-06-17 2001-08-07 Wisconsin Alumni Research Foundation Methods for making multivalent arrays
US6291616B1 (en) 1999-06-17 2001-09-18 Wisconsin Alumni Research Foundation Methods and reagents for capping ruthenium or osmium carbene-catalyzed ROMP products
AU784040B2 (en) 1999-06-25 2006-01-19 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
JP2004515208A (ja) 2000-03-28 2004-05-27 ナノスフェアー インコーポレイテッド オリゴヌクレオチドを付着させたナノ粒子とその使用方法
US6927033B2 (en) 2000-05-11 2005-08-09 Toudai Tlo, Ltd. Polymer composition for forming surface of biosensor
WO2002004681A2 (en) 2000-07-11 2002-01-17 Northwestern University Method of detection by enhancement of silver staining
EP1362121A2 (en) 2000-08-11 2003-11-19 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
US6726847B2 (en) 2000-12-06 2004-04-27 Northwestern University Silver stain removal by chemical etching and sonication
WO2002046472A2 (en) 2000-12-08 2002-06-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2002079490A2 (en) 2001-03-28 2002-10-10 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified particles
WO2003087188A1 (en) 2001-04-26 2003-10-23 Nanosphere, Inc. Oligonucleotide-modified romp polymers and co-polymers
US20030113740A1 (en) 2001-04-26 2003-06-19 Mirkin Chad A. Oligonucleotide-modified ROMP polymers and co-polymers
WO2002096262A2 (en) 2001-05-25 2002-12-05 Northwestern University Non-alloying core shell nanoparticles
US7147687B2 (en) 2001-05-25 2006-12-12 Nanosphere, Inc. Non-alloying core shell nanoparticles
DE60231309D1 (de) 2001-08-03 2009-04-09 Nanosphere Inc Nanopartikelabbildungssystem und -verfahren
WO2003035829A2 (en) 2001-10-09 2003-05-01 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2003081202A2 (en) 2001-11-09 2003-10-02 Nanosphere, Inc. Bioconjugate-nanoparticle probes
US20030211488A1 (en) 2002-05-07 2003-11-13 Northwestern University Nanoparticle probs with Raman spectrocopic fingerprints for analyte detection
EP1540006B1 (en) 2002-07-02 2009-01-07 Nanosphere, Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
JP2006517786A (ja) 2002-12-12 2006-08-03 ナノスフェアー　インコーポレイテッド 未増幅ｄｎａを用いた直接的ｓｎｐ検出

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4023981A (en) * 1974-06-14 1977-05-17 Produits Chimiques Ugine Kuhlmann Process for the preparation of pigmentary metallic particles coated with an organic polymer and compositions resulting therefrom
US4454234A (en) * 1981-12-30 1984-06-12 Czerlinski George H Coated magnetizable microparticles, reversible suspensions thereof, and processes relating thereto
US4846893A (en) * 1987-02-04 1989-07-11 Fuji Xerox Co., Ltd. Process for producing a surface treated pigment
US5053471A (en) * 1987-11-17 1991-10-01 Japan Synthetic Rubber Co., Ltd. Transparent resin material
US5736413A (en) * 1989-11-17 1998-04-07 Laboratoires Merck Clevenot Immunodiagnostic reagent for carrying out a multi-stage immunoassay of at least one biological substance in a plurality of biological samples
US5639620A (en) * 1990-10-31 1997-06-17 Coulter Corporation Polymeric particles having a biodegradable gelatin or aminodextran coating and process for making same
US5342909A (en) * 1992-04-03 1994-08-30 California Institute Of Technology Ruthenium and osmium metal carbene complexes for olefin metathesis polymerization
US5766764A (en) * 1996-06-04 1998-06-16 The Boeing Company Nanoscale amorphous magnetic metals

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812334B1 (en) 1996-07-29 2004-11-02 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6730269B2 (en) 1996-07-29 2004-05-04 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US8323888B2 (en) 1996-07-29 2012-12-04 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6969761B2 (en) 1996-07-29 2005-11-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6984491B2 (en) 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7259252B2 (en) 1996-07-29 2007-08-21 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7250499B2 (en) 1996-07-29 2007-07-31 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7208587B2 (en) 1996-07-29 2007-04-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7169556B2 (en) 1996-07-29 2007-01-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6645721B2 (en) 1996-07-29 2003-11-11 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6673548B2 (en) 1996-07-29 2004-01-06 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6677122B2 (en) 1996-07-29 2004-01-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6682895B2 (en) 1996-07-29 2004-01-27 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6709825B2 (en) 1996-07-29 2004-03-23 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6720147B2 (en) 1996-07-29 2004-04-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6720411B2 (en) 1996-07-29 2004-04-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6903207B2 (en) 1996-07-29 2005-06-07 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6902895B2 (en) 1996-07-29 2005-06-07 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6740491B2 (en) 1996-07-29 2004-05-25 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6759199B2 (en) 1996-07-29 2004-07-06 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6767702B2 (en) 1996-07-29 2004-07-27 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6773884B2 (en) 1996-07-29 2004-08-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6777186B2 (en) 1996-07-29 2004-08-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6962786B2 (en) 1996-07-29 2005-11-08 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6818753B2 (en) 1996-07-29 2004-11-16 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6828432B2 (en) 1996-07-29 2004-12-07 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6861221B2 (en) 1996-07-29 2005-03-01 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6878814B2 (en) 1996-07-29 2005-04-12 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6986989B2 (en) 1996-07-29 2006-01-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US8501921B2 (en) 1998-10-27 2013-08-06 Osmetech Technology, Inc. Detection of target analytes using particles and electrodes
US6541617B1 (en) 1998-10-27 2003-04-01 Clinical Micro Sensors, Inc. Detection of target analytes using particles and electrodes
US8012743B2 (en) 1998-10-27 2011-09-06 Osmetech Technology Inc. Detection of target analytes using particles and electrodes
US7115688B1 (en) 1998-11-30 2006-10-03 Nanosphere, Inc. Nanoparticles with polymer shells
US6908737B2 (en) 1999-04-15 2005-06-21 Vitra Bioscience, Inc. Systems and methods of conducting multiplexed experiments
US7253435B2 (en) 1999-04-15 2007-08-07 Millipore Corporation Particles with light-polarizing codes
WO2001060969A1 (en) * 2000-02-18 2001-08-23 Biophan, Llc Hybrid nucleic acid assembly
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US7323309B2 (en) 2000-03-28 2008-01-29 Northwestern University Bio-barcodes based on oligonucleotide-modified particles
US6602669B2 (en) 2000-07-11 2003-08-05 Northwestern University Method of detection by enhancement of silver staining
US7557070B2 (en) 2000-10-18 2009-07-07 Millipore Corporation Multiplexed cell analysis system
JP2005513999A (ja) * 2000-11-15 2005-05-19 ミナーヴァ・バイオテクノロジーズ・コーポレーション オリゴヌクレオチド識別子
JP2010142244A (ja) * 2000-11-15 2010-07-01 Minerva Biotechnologies Corp オリゴヌクレオチド識別子
WO2002044725A1 (en) * 2000-11-30 2002-06-06 Innotrac Diagnostics Oy Bioanalytical assay
US6726847B2 (en) 2000-12-06 2004-04-27 Northwestern University Silver stain removal by chemical etching and sonication
WO2002063304A3 (de) * 2001-02-08 2003-03-13 Ibidi Gmbh Probenträger für chemische und biologische proben
WO2003087188A1 (en) * 2001-04-26 2003-10-23 Nanosphere, Inc. Oligonucleotide-modified romp polymers and co-polymers
US7238472B2 (en) 2001-05-25 2007-07-03 Nanosphere, Inc. Non-alloying core shell nanoparticles
US7147687B2 (en) 2001-05-25 2006-12-12 Nanosphere, Inc. Non-alloying core shell nanoparticles
WO2002096262A3 (en) * 2001-05-25 2003-02-20 Univ Northwestern Non-alloying core shell nanoparticles
US7135055B2 (en) 2001-05-25 2006-11-14 Nanosphere, Inc. Non-alloying core shell nanoparticles
WO2003031561A1 (en) * 2001-10-10 2003-04-17 Biomed Solutions, Llc Hybrid nucleic acid assembly
KR100969086B1 (ko) 2001-10-10 2010-07-09 제이에스알 가부시끼가이샤 노르보르넨 유도체 및 그의 노르보르넨계 개환 중합체
US7186814B2 (en) 2001-11-09 2007-03-06 Nanosphere, Inc. Bioconjugate-nanoparticle probes
DE10203907A1 (de) * 2002-01-31 2003-08-21 Karlsruhe Forschzent Fluoreszierende Nanoteilchen und deren Herstellung
EP1496363A4 (en) * 2002-04-03 2005-05-18 Japan Science & Tech Agency SENSOR SIDE FOR BIOPUCE CARRIER OF NANOPARTICLES OF POLYETHYLENE GLYCOLATE
US7985539B2 (en) 2002-05-07 2011-07-26 Northwestern University Nanoparticle probes with raman spectroscopic fingerprints for analyte detection
US7253277B2 (en) 2002-07-02 2007-08-07 Nanosphere, Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
EP1439391A3 (en) * 2003-01-15 2005-07-27 Agilent Technologies, Inc. Biosensor systems and methods for determining the presence of biomolecules
EP1624306A4 (en) * 2003-04-30 2008-12-24 Chengdu Kuachang Medical Ind L DEVICE CONTAINING THE NANOSTRUCTURES USED FOR SEPARATION OR ANALYSIS AND MANUFACTURE AND APPLICATION THEREOF
WO2004111602A3 (en) * 2003-05-16 2006-09-28 Univ Rochester Colorimetric and fluorescent methods for sensing of oligonucleotides
US7488451B2 (en) 2003-09-15 2009-02-10 Millipore Corporation Systems for particle manipulation
US7766993B2 (en) 2004-09-10 2010-08-03 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7820394B2 (en) 2005-12-02 2010-10-26 Catassays Ultrasensitive bioanalytical assays based on the use of high-gain catalytic chemical amplification
WO2007065120A3 (en) * 2005-12-02 2007-08-02 Mark Lelental Ultransensitive chemically amplified bioanalytical assays
EP3449945A4 (en) * 2016-08-05 2020-06-10 Shenzhen Profound-View Pharma Tech Co., Ltd. SUBSTANCE WITH GOLD CLUSTER AND PRODUCTION METHOD AND USE THEREOF
EP4000636A3 (en) * 2016-08-05 2022-08-03 Shenzhen Profound-View Pharma Tech Co., Ltd. Substances containing aucs and preparation method and use thereof

Also Published As

Publication number Publication date
JP3650582B2 (ja) 2005-05-18
US7115688B1 (en) 2006-10-03
CA2352362C (en) 2009-02-17
CN1607390A (zh) 2005-04-20
AU1928600A (en) 2000-06-19
CN100406890C (zh) 2008-07-30
CA2352362A1 (en) 2000-06-08
CN1182395C (zh) 2004-12-29
EP1135682A1 (en) 2001-09-26
DE69936534D1 (de) 2007-08-23
JP2002531830A (ja) 2002-09-24
EP2000803A1 (en) 2008-12-10
CN1328641A (zh) 2001-12-26
EP1135682B1 (en) 2007-07-11
DE69936534T2 (de) 2008-03-13
EP1135682A4 (en) 2002-09-25
ATE366932T1 (de) 2007-08-15
AU768535B2 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
EP1135682B1 (en) Nanoparticles with polymer shells
AU2003247788B2 (en) Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
JP4665762B2 (ja) 非特異吸着を抑制した基材表面
US8716420B2 (en) Amphiphilic polymers and nanocrystals coated therewith
Lim et al. Gold and magnetic oxide/gold core/shell nanoparticles as bio-functional nanoprobes
CN100593546C (zh) 含有无机纳米微粒的聚合物微球及其制备方法和用途
WO2010074369A1 (en) Bioprobe, method of preparing the bioprobe, and analysis apparatus and method using the bioprobe
Bavireddi et al. Glyco-β-cyclodextrin capped quantum dots: synthesis, cytotoxicity and optical detection of carbohydrate–protein interactions
US20060286684A1 (en) Sensors for detecting an analyte using silver nanoparticles
JP2001503856A (ja) 多重アレイの多重特異的な電気化学発光試験
GB2474456A (en) Dendrimer functionalised nanoparticle label
CN102866139B (zh) 基于表面等离子体增强能量转移生物传感器的构建方法
Gokarna et al. Quantum dot‐based protein micro‐and nanoarrays for detection of prostate cancer biomarkers
JP2019527248A (ja) ポリマー−シリカハイブリッドＰｄｏｔおよびこれらを使用する方法
EP3853321B1 (en) Light-emitting marker particles
Choi et al. Conjugation of the photoluminescent silicon nanoparticles to streptavidin
US9933421B2 (en) Catalytic marking nanoparticles for ultrasensitive bioassay applications
CN116754757A (zh) 一种用于均相化学发光分析的供体颗粒及其应用
AU2004223618A1 (en) Sensor for detecting an analyte using silver nanoparticles
Zhang et al. A novel method to make hydrophilic quantum dots and its application on biodetection
WO2008035569A1 (fr) réactif de détection de biomolécule et procédé de détection de biomolécule utilisant le réactif
CN112240930A (zh) 一种均相化学发光分析的方法及其应用
Linares et al. One-step synthesis of polymer core–shell particles with a carboxylated ruthenium complex: A potential tool for biomedical applications
CN112240928A (zh) 一种均相化学发光分析的方法及其应用
CN1542450A (zh) 用于荧光免役检测的CdSe纳米晶复合脂质体微囊泡的制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813888.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2352362

Country of ref document: CA

Ref document number: 2352362

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 19286/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 585664

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999962951

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09830620

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999962951

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 19286/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999962951

Country of ref document: EP